Lexaria Bioscience Corp. (LEXX)
Automate Your Wheel Strategy on LEXX
With Tiblio's Option Bot, you can configure your own wheel strategy including LEXX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LEXX
- Rev/Share 0.03
- Book/Share 0.3861
- PB 2.2579
- Debt/Equity 0.0173
- CurrentRatio 4.2386
- ROIC -1.369
- MktCap 17948845.0
- FreeCF/Share -0.4268
- PFCF -2.4017
- PE -1.7192
- Debt/Assets 0.0143
- DivYield 0
- ROE -1.07
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
Published: May 12, 2025 by: TheNewswire
Sentiment: Neutral
Kelowna, British Columbia – TheNewswire - May 12, 2025 - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on corporate developments. Lexaria previously announced, on September 3, 2024, that it had entered into a Material Transfer Agreement (“MTA”) with a pharmaceutical company (“PharmaCO”) to evaluate Lexaria's DehydraTECH TM technology in a pre-clinical setting.
Read More
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral
KELOWNA, BC / ACCESS Newswire / May 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on corporate developments. Lexaria previously announced, on September 3, 2024, that it had entered into a Material Transfer Agreement ("MTA") with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECHTM technology in a pre-clinical setting.
Read More
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology
Published: April 23, 2025 by: Accesswire
Sentiment: Neutral
Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry Lexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") strategic update following important industry developments reported both by Pfizer® Inc. and by Eli Lilly and Company®. Nearly all of the world's top pharmaceutical companies are racing to develop new oral GLP-1 drugs, including: Amgen®, AstraZenca, Eli Lilly, Merck®, Novo Nordisk®, Pfizer®, and Roche®.
Read More
Lexaria's Human GLP-1 Study #5 Begins Dosing
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral
Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide Study will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April 2, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that dosing has begun as scheduled in its human study GLP-1-H25-5 (the "Study") that is comparing oral DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide. On November 20, 2024, Lexaria reported on an earlier 12-week study in rodents which showed that with unlimited food available, oral DehydraTECH-liraglutide demonstrated a 5.88% weight reduction and an 11.54% blood sugar …
Read More
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)
Published: March 18, 2025 by: Accesswire
Sentiment: Neutral
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound® As previously announced, oral DehydraTECH-tirzepatide also reduced adverse events by 47% compared to injected Zepbound® Lexaria's oral capsules worthy of expanded investigation as a viable alternative to injected tirzepatide. KELOWNA, BC / ACCESS Newswire / March 18, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce positive pharmacokinetic ("PK") results from Human Study #3 or GLP-1-H24-3 (the "Study"), comparing an oral version of DehydraTECH-processed Zepbound® ("DehydraTECH-tirzepatide") …
Read More
Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound
Published: March 18, 2025 by: TheNewswire
Sentiment: Neutral
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound As previously announced, oral DehydraTECH-tirzepatide also reduced adverse events by 47% compared to injected Zepbound
Read More
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Published: February 27, 2025 by: TheNewswire
Sentiment: Neutral
Lexaria executing a triple-pronged strategy in obesity and diabetes Semaglutide recently approved to treat chronic kidney disease
Read More
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
Lexaria executing a triple-pronged strategy in obesity and diabetes Semaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") strategic update. Lexaria is rapidly executing its multi-faceted strategy centered around its proprietary DehydraTECH processing technology.
Read More
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Published: February 24, 2025 by: TheNewswire
Sentiment: Neutral
5 th study arm in 12-week Phase 1b Study receives lead clinical site approval Kelowna, British Columbia – February 24, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee (“HREC” ) approval that was required before dosing can begin in the 5 th study arm of the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the “ Study ”) in Australia.
Read More
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
5th study arm in 12-week Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee ("HREC") approval that was required before dosing can begin in the 5th study arm of the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study") in Australia. This news complements similar news issued on November 13, 2024, when initial lead clinical site HREC approval was received for the first 4 arms …
Read More
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has made a strategic business decision to further investigate the commercial opportunities and applications for a unique new GLP-1 solution: orally taken liraglutide processed with our wholly-owned DehydraTECH™ enhancement technology. "Our ability to work with liraglutide, which went off-patent last year, is an opportunity that does not often present itself," said Rich Christopher, CEO of Lexaria.
Read More
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Published: February 20, 2025 by: TheNewswire
Sentiment: Neutral
Pursuing the world's first-ever orally-dosed liraglutide Kelowna, British Columbia – February 20, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has made a strategic business decision to further investigate the commercial opportunities and applications for a unique new GLP-1 solution: orally taken liraglutide processed with our wholly-owned DehydraTECH™ enhancement technology.
Read More
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Published: February 11, 2025 by: TheNewswire
Sentiment: Neutral
Additions broaden DehydraTECH patent suite for Epilepsy Kelowna, British Columbia – TheNewswire - February 11, 2025 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that we have been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH™ enhanced processing technology related to the treatment of epilepsy.
Read More
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
Additions broaden DehydraTECH patent suite for Epilepsy KELOWNA, BC / ACCESS Newswire / February 11, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that we have been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH™ enhanced processing technology related to the treatment of epilepsy. "We are thrilled to have received broadened claims related to our proprietary DehydraTECH™ technology for the treatment of epilepsy," said Rich Christopher, CEO of Lexaria.
Read More
About Lexaria Bioscience Corp. (LEXX)
- IPO Date 2021-01-12
- Website https://www.lexariabioscience.com
- Industry Biotechnology
- CEO Mr. Richard C. Christopher
- Employees 7